Indivior PLC (NASDAQ:INDV) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Indivior PLC (NASDAQ:INDV) have been given an average recommendation of “Moderate Buy” by the seven brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $39.3333.

A number of brokerages recently weighed in on INDV. Northland Securities set a $50.00 price objective on Indivior in a research note on Tuesday, January 20th. Morgan Stanley reissued an “overweight” rating and issued a $36.00 price target on shares of Indivior in a research report on Wednesday, December 3rd. Zacks Research downgraded shares of Indivior from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 13th. Weiss Ratings upgraded shares of Indivior from a “hold (c)” rating to a “buy (b-)” rating in a research note on Monday. Finally, HC Wainwright boosted their target price on shares of Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a research report on Monday, January 12th.

Insider Activity

In other Indivior news, Director Daniel A. Ninivaggi bought 775 shares of the stock in a transaction on Monday, January 5th. The shares were purchased at an average price of $35.39 per share, with a total value of $27,427.25. Following the acquisition, the director directly owned 16,923 shares of the company’s stock, valued at $598,904.97. This represents a 4.80% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director David E. Wheadon purchased 1,771 shares of the company’s stock in a transaction on Monday, January 5th. The stock was acquired at an average cost of $35.39 per share, for a total transaction of $62,675.69. Following the completion of the transaction, the director owned 14,395 shares in the company, valued at approximately $509,439.05. This trade represents a 14.03% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 4,871 shares of company stock worth $172,385 over the last 90 days.

Hedge Funds Weigh In On Indivior

Large investors have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd boosted its holdings in Indivior by 72.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock valued at $39,000 after purchasing an additional 460 shares during the period. Virtu Financial LLC bought a new stake in Indivior in the 4th quarter valued at $344,000. Invesco Ltd. raised its stake in shares of Indivior by 274.6% in the 4th quarter. Invesco Ltd. now owns 286,689 shares of the company’s stock valued at $10,286,000 after buying an additional 210,150 shares in the last quarter. Mercer Global Advisors Inc. ADV bought a new position in shares of Indivior during the 4th quarter worth about $274,000. Finally, EP Wealth Advisors LLC acquired a new stake in shares of Indivior during the 4th quarter valued at about $481,000. 60.33% of the stock is currently owned by institutional investors and hedge funds.

Indivior Trading Down 3.5%

Indivior stock opened at $30.87 on Wednesday. Indivior has a 1-year low of $8.64 and a 1-year high of $38.00. The firm’s fifty day simple moving average is $34.35 and its 200-day simple moving average is $30.21. The company has a market capitalization of $3.86 billion, a P/E ratio of 18.82 and a beta of 0.83.

Indivior (NASDAQ:INDV) last posted its earnings results on Thursday, February 26th. The company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.65 by $0.17. Indivior had a net margin of 16.85% and a negative return on equity of 148.76%. The firm had revenue of $358.00 million for the quarter, compared to the consensus estimate of $305.62 million. On average, equities research analysts predict that Indivior will post 1.22 earnings per share for the current year.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.